预约演示
更新于：2025-01-18
Tozadenant
更新于：2025-01-18
概要
基本信息
在研机构- |
最高研发阶段终止临床3期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H26N4O4S |
InChIKeyXNBRWUQWSKXMPW-UHFFFAOYSA-N |
CAS号870070-55-6 |
关联
8
项与 Tozadenant 相关的临床试验NCT03200080
A Randomized, Double-Blind, 6-Way Crossover Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug Users With Stimulant Experience, Under Fed Conditions
This will be a single-dose, randomized, double-blind, active- and placebo-controlled, double dummy, 6-way crossover study to determine the abuse potential of tozadenant relative to d-amphetamine and placebo, when administered orally in healthy non-dependent, recreational polydrug users with stimulant experience, under fed conditions.
Each subject will participate in a medical Screening visit, a 4-day (3-night) qualification (drug discrimination) visit, six 3-day (2-night) treatment periods, and a follow-up visit.
Each subject will participate in a medical Screening visit, a 4-day (3-night) qualification (drug discrimination) visit, six 3-day (2-night) treatment periods, and a follow-up visit.
开始日期2017-09-18 |
申办/合作机构 Biotie Therapies Oy [+1] |
NCT03212313
A Two-Part, Open-Label, Single-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant
This is a two-part, open label, single-dose study that will evaluate the PK of tozadenant in subjects with different degrees of hepatic impairment to the PK of a single-dose of tozadenant in healthy subjects.
开始日期2017-06-30 |
申办/合作机构 Biotie Therapies Oy [+1] |
NCT03051607
A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose "Wearing-Off"
Phase 3, international, multicenter, open-label 12 month safety study.
开始日期2017-04-10 |
申办/合作机构 Biotie Therapies Oy [+1] |
100 项与 Tozadenant 相关的临床结果
登录后查看更多信息
100 项与 Tozadenant 相关的转化医学
登录后查看更多信息
100 项与 Tozadenant 相关的专利（医药）
登录后查看更多信息
40
项与 Tozadenant 相关的文献（医药）2023-06-01·The Journal of pediatrics
Adverse Effects of α-2 Adrenergic Agonists and Stimulants in Preschool-age Attention-deficit/Hyperactivity Disorder: A Developmental–Behavioral Pediatrics Research Network Study
Article
作者: Loe, Irene M ; Friedman, Sandra ; Barbaresi, William ; Vanderbilt, Douglas ; Shults, Justine ; Cacia, Jaclyn ; Mittal, Shruti ; Deavenport-Saman, Alexis ; Blum, Nathan J ; Bax, Ami ; LaRosa, Angela ; Harstad, Elizabeth
OBJECTIVES:
To characterize and compare the type and frequency of a range of common and uncommon adverse effects (AEs) associated with α-2 adrenergic agonist (A2A) and stimulant treatment of attention-deficit/hyperactivity disorder at preschool-age as well as to evaluate the impact of age on common AEs.
STUDY DESIGN:
This was a retrospective electronic medical record review of children <72 months of age (n = 497) evaluated at outpatient developmental-behavioral pediatric practices at 7 US academic medical centers within the Developmental-Behavioral Pediatrics Research Network. Data on AEs were abstracted for children who had treatment initiated by a developmental-behavioral pediatrician with an A2A or stimulant medication between January 2013 and July 2017; follow-up was complete by February 2019.
RESULTS:
A2A and stimulants had distinctive AE profiles. A2A compared with stimulants had a greater proportion with daytime sleepiness and headaches; stimulants had significantly greater proportions for most other AE, including moodiness/irritability, difficulty with sleep, appetite suppression, stomachaches, skin picking/repetitive behaviors, withdrawn behavior, and weight loss. Younger age was associated with disruptive behavior and difficulty with sleep.
CONCLUSIONS:
Stimulants had a greater rate of most AEs compared with A2A. AE profiles, together with efficacy, should inform clinical decision-making. Prospective randomized clinical trials are needed to fully compare efficacy and AE profiles of A2A and stimulants.
2022-09-01·The Science of the total environment2区 · 环境科学与生态学
Climate change simulation and trend analysis of extreme precipitation and floods in the mesoscale Rur catchment in western Germany until 2099 using Statistical Downscaling Model (SDSM) and the Soil & Water Assessment Tool (SWAT model)
2区 · 环境科学与生态学
Article
作者: Korres, Wolfgang ; Eingrüber, Nils
Due to climate change and global warming, speed and intensity of the hydrological cycle will accelerate. In order to carry out regional risk assessment, integrated water resources management and flood protection, far reaching predictions and future scenarios of climate change effects on extreme precipitation and flooding are of particular relevance. In this study, trends in frequencies of extreme precipitation and floods until 2099 are analysed for the German Rur catchment, which is half located in highlands and half in lowlands and therefore has a high topographical and climatological contrast. To predict future trends, coupled modeling is performed based on NCEP reanalysis data and a General Circulation Model (GCM). Assuming HadCM3 future emission scenarios A2a and B2a, an empirical Statistical Downscaling Model (SDSM) is developed and daily precipitation amounts are projected until 2099 by a stochastic weather generator. The generated precipitation data are used as an input for the ecohydrological Soil & Water Assessment Tool (SWAT model) to simulate daily water discharge until 2099. Statistical trend analyses are implemented based on three annual extreme precipitation indices (EPIs) and the magnitudes of ten flood return periods derived with GEV and Gumbel extreme value distributions for 109 30-year moving periods using regression analyses and Mann-Kendall tendency tests to check for significant trends in the frequencies until 2099. As a result, it could be demonstrated for all EPIs that the frequency of extreme precipitation in the upper Rur catchment will significantly increase by +33% to +51% until 2099 compared to the base period 1961-1990, whereas mostly non-significant negative trends of extreme precipitation can be projected in the lowlands. For runoff, it was found that the magnitudes of the ten flood return periods will significantly increase by +31% for B2a to +36% for A2a until 2099 compared to the base period.
2022-08-01·Journal of child and adolescent psychopharmacology
Association of Coexisting Conditions, Attention-Deficit/Hyperactivity Disorder Medication Choice, and Likelihood of Improvement in Preschool-Age Children: A Developmental Behavioral Pediatrics Research Network Study
Article
作者: Deavenport-Saman, Alexis ; Barbaresi, William ; Friedman, Sandra ; Shults, Justine ; Mittal, Shruti ; Cacia, Jaclyn ; Loe, Irene ; LaRosa, Angela ; Vanderbilt, Douglas L. ; Harstad, Elizabeth ; Blum, Nathan ; Bax, Ami
Objectives: To determine whether conditions coexisting with attention-deficit/hyperactivity disorder (ADHD) in preschool-age children are associated with choice of stimulants or alpha-2 adrenergic agonists (A2As) and/or likelihood of improvement in ADHD symptoms. Methods: A retrospective electronic health record review of 497 children from 7 Developmental Behavioral Pediatrics Research Network (DBPNet) sites. Children were <72 months when treated with medication for ADHD from January 1, 2013 to July 1, 2017. We abstracted coexisting conditions, initial medication prescribed, and whether the medication was associated with improvement in symptoms. Analysis of improvement was adjusted for clustering by clinician and site. Results: The median (interquartile range) child age at the time of initiation of ADHD medication was 62 (54-67) months. The most common coexisting conditions included language disorders (40%), sleep disorders (28%), disruptive behavior disorders (22.7%), autism spectrum disorder (ASD; 21.8%), and motor disorders (19.9%). No coexisting conditions were present in 17.1%; 1 in 36.8%, 2 in 26.8%, and ≥3 in 19.3%. Stimulants were initially prescribed for 322 (64.8%) and A2A for 175 (35.2%) children. Children prescribed stimulants were more likely to have no coexisting conditions than those prescribed A2A (22.3% vs. 7.4%; p < 0.001). Coexisting ASD and sleep disorder were associated with increased likelihood of starting A2As versus stimulants (p < 0.0005; p = 0.002). The association between medication treatment and improvement varied by number of coexisting conditions for 0, 1, 2, or ≥3, respectively (84.7%, 73.8%, 72.9%, 64.6%; p = 0.031). Children with ≥3 coexisting conditions were less likely to respond to stimulants than children with no coexisting conditions (67.4% vs. 79.9%; p = 0.037). Conclusions: Among preschool-age children with ADHD, those with ≥3 coexisting conditions were less likely to respond to stimulants than those with no coexisting conditions. This was not found for A2A, but further research is needed as very few children with no coexisting conditions were treated with A2A.
1
项与 Tozadenant 相关的新闻（医药）2017-12-09
Summary
Biotie Therapies Corp Biotie is a pharmaceutical company that discovers and develops new medicines for the treatment of various diseases. The company offers products for use in the treatment of neurodegenerative and psychiatric disorders such as parkinson's disease, alzheimer's disease, primary sclerosing cholangitis and other cognitive disorders; and inflammatory and fibrotic diseases. Its products under clinical development include Selincro, an opioid receptor ligand; Tozadenant, an innovative A2a antagonist; SYN120, a selective 5HT6 receptor antagonist; and BTT1023, a monoclonal antibody, among others. The company has presence in Finland and the US. Biotie is headquartered in Turku, Finland.
Biotie Therapies Corp Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions.
GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research.
Scope
Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector.
Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.
Business Description A brief description of the company's operations.
Key Employees A list of the key executives of the company.
Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company.
Key Competitors A list of the key competitors of the company.
Key Recent Developments A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay uptodate on the major developments affecting the company
Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
抗体并购
100 项与 Tozadenant 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D10174 | Tozadenant | - |
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 帕金森病 | 临床3期 | 奥地利 | 2015-07-01 | |
| 帕金森病 | 临床3期 | 捷克 | 2015-07-01 | |
| 帕金森病 | 临床3期 | 德国 | 2015-07-01 | |
| 帕金森病 | 临床3期 | 意大利 | 2015-07-01 | |
| 帕金森病 | 临床3期 | 西班牙 | 2015-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床3期 | 66 | 夢壓觸構獵襯鹽膚廠淵(餘壓廠廠夢觸簾構鬱選) = 製廠淵齋顧膚築憲範築 簾範繭膚壓鑰蓋窪選簾 (積襯鬱選窪憲鑰壓衊選, 憲壓鏇築廠衊衊廠襯鹽 ~ 鹹鏇廠簾鏇鹹鹽獵簾觸) 更多 | - | 2019-05-03 | |||
临床3期 | 449 | placebo (Placebo BID) | 顧襯鹹積鏇製鑰憲積範(醖製憲醖製襯壓壓築鑰) = 衊艱醖壓鹽襯醖觸醖獵 構窪廠願齋淵積鬱鏇顧 (夢廠簾鬱願願廠醖齋獵, 窪獵鹽襯餘膚選淵糧艱 ~ 窪餘願夢繭遞鏇選積網) 更多 | - | 2019-03-26 | ||
(Tozadenant 60 mg BID) | 顧襯鹹積鏇製鑰憲積範(醖製憲醖製襯壓壓築鑰) = 獵繭夢繭餘艱艱範獵網 構窪廠願齋淵積鬱鏇顧 (夢廠簾鬱願願廠醖齋獵, 艱窪簾餘鹹鏇膚鏇廠襯 ~ 鹹壓網築艱鹹選襯積膚) 更多 | ||||||
临床3期 | - | TOZ 30 mg/kg | 構憲蓋窪繭簾簾網築鬱(蓋積簾艱夢醖積衊餘觸) = 構餘顧獵簾網鹽壓鏇艱 艱衊積夢醖衊願網網簾 (鏇鏇齋蓋構構糧範積窪 ) | - | 2017-06-04 | ||
N/A | 247 | 範願鬱製餘鑰鬱鬱築繭(顧衊醖淵壓膚糧顧鏇選) = 鏇網顧憲淵顧鹹衊繭齋 窪夢膚艱餘壓衊鹽獵夢 (顧膚蓋顧觸淵齋簾鏇積 ) | 积极 | 2017-06-04 | |||
範願鬱製餘鑰鬱鬱築繭(顧衊醖淵壓膚糧顧鏇選) = 鹹遞製壓顧遞獵築繭製 窪夢膚艱餘壓衊鹽獵夢 (顧膚蓋顧觸淵齋簾鏇積 ) | |||||||
N/A | - | New antagonist A2a (A15PrOH) | 窪觸遞範廠積製餘範鹽(觸憲糧廠憲鹽繭憲廠憲) = 蓋襯鑰鹹顧網構蓋構醖 網餘簾蓋願艱簾廠範艱 (鏇鑰糧糧築艱窪網夢選 ) | - | 2001-11-12 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用